We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Whole-Genome Sequencing Diagnoses Neurological Repeat Expansion Disorders

By LabMedica International staff writers
Posted on 25 Feb 2022
Print article
Image: Schematic Diagram of Whole-Genome Sequencing that was used to diagnose neurological repeat expansion disorders (Photo courtesy of Centers of Disease Control and Prevention)
Image: Schematic Diagram of Whole-Genome Sequencing that was used to diagnose neurological repeat expansion disorders (Photo courtesy of Centers of Disease Control and Prevention)

Scientists have found whole genome sequencing (WGS) can quickly and accurately detect the most common inherited neurological disorders – something previously thought to be impossible – with the results supporting the use of WGS as a standard diagnostic tool within routine clinical practice.

Repeat expansion disorders are clinically heterogeneous diseases that affect about 1 in every 3,000 people and are caused by expansions of short tandem DNA repeats. Examples of such disorders include Fragile X syndrome, Huntington’s disease, Friedreich's ataxia, and some forms of amyotrophic lateral sclerosis.

Whole genome sequencing is emerging as a first-line diagnostic tool in patients with rare disease but, until recently, was thought to have limited capability to assess loci containing repeat expansions. Advances in bioinformatics, however, have made feasible the detection of disease-causing repeat expansions from next-generation sequencing data.

Medical Scientists specializing in Molecular Genetics at the Queen Mary University of London (London, UK) and their associates evaluated whole genome sequencing for detection of repeat expansions included both diagnostic accuracy and clinical accuracy assessments. Diagnostic accuracy was evaluated using data from patients who had previously been tested by PCR for repeat expansions known to cause neurological disease.

The team retroactively looked at the accuracy of whole-genome sequencing to detect the 13 most common repeat expansion loci associated with neurological outcomes, using samples from NHS patients thought to have neurological disorders who were recruited between 2013 and 2017 as part of the 100,000 Genomes Project. They used earlier PCR test results for the loci in 404 patients as a reference standard. When whole-genome sequencing of patient samples resulted in a repeat expansion call, they used PCR again to confirm those calls.

The scientists reported that whole-genome sequencing showed 97.3% sensitivity and 99.6% specificity for detecting repeat expansions across the 13 loci, compared to PCR results. They also looked at samples from 11,631 undiagnosed patients with suspected repeat expansions, based on their clinical features, from the 100,000 Genomes Project. They were able to tag 81 repeat expansions in these, 68 of which were in the full pathogenic range providing these patients with a diagnosis.

Sir Mark Jonathan Caulfield MD, FRCP, FESC, FPharm, FBHS, FMedSci, a Professor of Pharmacology, and a senior author of the study, said, “At the moment, diagnosing this type of neurological disorder often depends on people having a family history of the disease or specific clinical symptoms. Using whole-genome sequencing, we can detect these and new repeat expansion disorders.”

The authors concluded that whole genome sequencing for the detection of repeat expansions showed high sensitivity and specificity, and it led to identification of neurological repeat expansion disorders in previously undiagnosed patients. These findings support implementation of whole genome sequencing in clinical laboratories for diagnosis of patients who have a neurological presentation consistent with a repeat expansion disorder. The study was published on March 01, 2022 in the journal The Lancet Neurology.

Related Links:
Queen Mary University of London 

New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Automated Blood Typing System
IH-500 NEXT
New
Urine Bone Markers Control
Lyphochek Urine Bone Markers Control
New
Silver Member
Static Concentrator
BJP 10

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The AI program analyzes a microscopy image from a tumor biopsy and determines what genes are likely turned on and off in the cells it contains (Photo courtesy of Olivier Gevaert/Stanford Medicine)

AI Tool ‘Sees’ Cancer Gene Signatures in Biopsy Images

To assess the type and severity of cancer, pathologists typically examine thin slices of a tumor biopsy under a microscope. However, to understand the genomic alterations driving the tumor's growth, scientists... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.